Gain Therapeutics, Inc. (GANX) vs iBio, Inc. (IBIO)
A side-by-side comparison of Gain Therapeutics, Inc. and iBio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GANX
Gain Therapeutics, Inc.
$1.67HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
IBIO
iBio, Inc.
$1.05HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — GANX vs IBIO
growth of $100 · dividends reinvested · last 6yGANX -84.9% (-27.0%/yr)IBIO -99.9% (-67.0%/yr)GANX compounded faster over this window
Log scale — wide-divergence pair
GANX IBIO
GANX vs IBIO: by the numbers
- •GANX is the larger company ($71M vs $68M market cap).
- •Both run net losses; GANX's is the smaller (0.00% vs -33044.00% net margin).
Metrics side by side
Valuation
| Metric | GANX | IBIO |
|---|---|---|
| P/S ratio | N/A | 675.23 |
| P/B ratio | 6.31 | 0.79 |
Profitability
| Metric | GANX | IBIO |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -35141.00% |
| Net margin | 0.00% | -33044.00% |
| ROE | -178.06% | -38.55% |
| ROIC | -159.24% | -40.22% |
Growth (annualized)
| Metric | GANX | IBIO |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -46.91% |
| Total return CAGR (5Y) | -25.06% | -70.43% |
Frequently asked
- How have GANX and IBIO total returns compared?
- Over the past 5 years, GANX delivered -25.06% and IBIO delivered -70.43% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.